C. Martínez-Vila

COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry

R. Salazar, A. Maconi, F. Mazzoni, 2022, Journal of the National Cancer Institute.

Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

M. Piccart, M. Filetti, R. Salazar, 2022, The Lancet Oncology.

Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry

F. Grosso, F. Mazzoni, P. Pedrazzoli, 2022, European Journal of Cancer.

Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry.

R. Salazar, F. Mazzoni, N. Harbeck, 2021, JAMA oncology.

Encephalitis Associated With Immune Checkpoint Inhibitor Treatment in Patients With Melanoma

J. Laguna, L. Gaba, A. A. Arance Fernandez, 2021, Journal of immunotherapy.

Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma.

R. Sullivan, P. Ascierto, J. McQuade, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer

A. Bertuzzi, A. Prat, A. Cortellini, 2022, British Journal of Cancer.

Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

M. Filetti, R. Salazar, A. Maconi, 2022, European Journal of Cancer.

Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

M. Piccart, M. Filetti, R. Salazar, 2021, The Lancet Oncology.

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.

L. Pickering, Douglas B. Johnson, C. Blank, 2022, European journal of cancer.